Browsing Category

65322 posts
Global Leading Crypto Exchange BingX Makes Move Into Latin American Fiat-to-Crypto Payments

Global Leading Crypto Exchange BingX Makes Move Into Latin American Fiat-to-Crypto Payments

VILNIUS, Lithuania, March 19, 2024 /PRNewswire/ — In a significant step towards…
SATO NAMED AS A WINNER OF FAST COMPANY'S INNOVATION AWARD

SATO NAMED AS A WINNER OF FAST COMPANY'S INNOVATION AWARD

The award in the Social Good category recognises SATO’s relentless focus on…
SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential

SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential

SHANGHAI, March 19, 2024 /PRNewswire/ — Mabwell (688062.SH), an innovative-driven biopharmaceutical company with entire…
TECNO's Security Response Center Authorized by the CVE Program

TECNO's Security Response Center Authorized by the CVE Program

HONG KONG, March 19, 2024 /PRNewswire/ — Innovative technology brand TECNO is…
300mm Fab Equipment Spending Forecast to Reach Record 7 Billion in 2027, SEMI Reports

300mm Fab Equipment Spending Forecast to Reach Record $137 Billion in 2027, SEMI Reports

MILPITAS, Calif., March 19, 2024 /PRNewswire/ — Global 300mm fab equipment spending for…
Datasea Enters into Manufacturing Agreement to Accelerate Production and Deployment of its Hi-Tech Intelligent Acoustic Products

Datasea Enters into Manufacturing Agreement to Accelerate Production and Deployment of its Hi-Tech Intelligent Acoustic Products

BEIJING, March 19, 2024 /PRNewswire/ — Datasea Inc. (Nasdaq: DTSS) ("Datasea" or…
Bybit Web3 Ignites the Bitcoin Layer2 Season with 100,000 MERL Airdrop

Bybit Web3 Ignites the Bitcoin Layer2 Season with 100,000 MERL Airdrop

DUBAI, UAE, March 19, 2024 /PRNewswire/ — Bybit, one the world’s top three…
Bill & Melinda Gates Medical Research Institute Initiates Phase 3 Clinical Trial of Tuberculosis Vaccine Candidate

Bill & Melinda Gates Medical Research Institute Initiates Phase 3 Clinical Trial of Tuberculosis Vaccine Candidate

A large Phase 3 trial will evaluate whether the M72/AS01E vaccine candidate…